ArticleJournal of virology2017
IRF9 Prevents CD8
Open access · bronzeAbstract read
In one paragraph
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 40 citations in OpenAlex.
- Altered increase in STAT1 expression and phosphorylation in severe COVID-19.European journal of immunology · 2022Trial
- Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026Review
- Inflammatory monocytes constrain YAP-induced cell proliferation.Science advances · 2026Article
- Semaphorin 6D drives anti-tumor type I interferon responses to reprogram the tumor microenvironment in colorectal cancer.Cell death & disease · 2026Article
- Interferon Regulatory Factors in Alcohol-Associated Liver Disease: Cell-Type Programs, Danger Signaling, and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
- Tumor-driven stabilization of CD8Frontiers in immunology · 2026Review
- Context-dependent impact of type I interferon signaling in cancer.Molecular cancer · 2025Review
- Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties.Cell reports. Medicine · 2025Article
- Mechanisms of Interleukin-10-Mediated Immunosuppression in Viral Infections.Pathogens (Basel, Switzerland) · 2025Review
- Transcription factor IRF-5 regulates lipid metabolism and mitochondrial function in murine CD8The EMBO journal · 2025Article
- Genomic analysis of progenitors in viral infection implicates glucocorticoids as suppressors of plasmacytoid dendritic cell generation.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- CD8Viruses · 2024Article
- Twist1-IRF9 Interaction Is Necessary for IFN-Stimulated Gene Anti-Zika Viral Infection.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Evolution and emergence of primate-specific interferon regulatory factor 9.Journal of medical virology · 2023Article
- EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.Cell stem cell · 2022Article
- Identification of hub biomarkers and immune cell infiltration in polymyositis and dermatomyositis.Aging · 2022Article
- T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy.Frontiers in immunology · 2022Review
- Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy.Frontiers in oncology · 2022Article
- Dynamic regulatory networks of T cell trajectory dissect transcriptional control of T cell state transition.Molecular therapy. Nucleic acids · 2021Article
- Genetic Exchange of Lung-Derived Exosome to Brain Causing Neuronal Changes on COVID-19 Infection.Molecular neurobiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Magdalena HuberInstitute of Medical Microbiology and Hygiene, University of Marburg, Marburg, Germany magdalena.huber@staff.uni-marburg.de markus.hofer@sydney.edu.au.
Tamara SuprunenkoSchool of Life and Environmental Sciences, the Marie Bashir Institute for Infectious Diseases and Biosecurity, the Charles Perkins Centre, and the Bosch Institute, The University of Sydney, Sydney, Australia.
Thomas AshhurstDepartment of Pathology and the Bosch Institute, School of Medical Sciences, Sydney Medical School, University of Sydney, Sydney, Australia, and Sydney Cytometry Facility, The University of Sydney and the Centenary Institute, Sydney, Australia.
Felix MarbachInstitute of Medical Microbiology and Hygiene, University of Marburg, Marburg, Germany.
Hartmann RaiferInstitute of Medical Microbiology and Hygiene, University of Marburg, Marburg, Germany.
Svenja WolffInstitute of Virology, University of Marburg, Marburg, Germany.
Thomas StreckerInstitute of Virology, University of Marburg, Marburg, Germany.
Barney ViengkhouSchool of Life and Environmental Sciences, the Marie Bashir Institute for Infectious Diseases and Biosecurity, the Charles Perkins Centre, and the Bosch Institute, The University of Sydney, Sydney, Australia.
So Ri JungSchool of Life and Environmental Sciences, the Marie Bashir Institute for Infectious Diseases and Biosecurity, the Charles Perkins Centre, and the Bosch Institute, The University of Sydney, Sydney, Australia.
Hannah-Lena ObermannInstitute of Immunology, University of Marburg, Marburg, Germany.
Stefan BauerInstitute of Immunology, University of Marburg, Marburg, Germany.
Haifeng C XuInstitute of Molecular Medicine II, University of Düsseldorf, Düsseldorf, Germany.
Philipp A LangInstitute of Molecular Medicine II, University of Düsseldorf, Düsseldorf, Germany.
Adomati TomInstitute of Immunology, University Hospital Essen, Essen, Germany.
Karl S LangInstitute of Immunology, University Hospital Essen, Essen, Germany.
Nicholas J C KingDepartment of Pathology and the Bosch Institute, School of Medical Sciences, Sydney Medical School, University of Sydney, Sydney, Australia, and Sydney Cytometry Facility, The University of Sydney and the Centenary Institute, Sydney, Australia.
Iain L CampbellSchool of Molecular Bioscience, the Marie Bashir Institute for Infectious Diseases and Biosecurity, the Charles Perkins Centre, and the Bosch Institute, The University of Sydney, Sydney, Australia.
Markus J HoferSchool of Life and Environmental Sciences, the Marie Bashir Institute for Infectious Diseases and Biosecurity, the Charles Perkins Centre, and the Bosch Institute, The University of Sydney, Sydney, Australia magdalena.huber@staff.uni-marburg.de markus.hofer@sydney.edu.au.ORCID http://orcid.org/0000-0001-5111-3978
Philipps University of Marburg · DEThe University of Sydney · AUEssen University Hospital · DEHeinrich Heine University Düsseldorf · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective CD8
Indexed as
Acute DiseaseAnimalsCD8-Positive T-LymphocytesChronic DiseaseInterferon Regulatory Factor-7Interferon-Stimulated Gene Factor 3, gamma SubunitInterferon Type ILymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMiceMice, KnockoutReceptor, Interferon alpha-betaSignal TransductionIfnar1 protein, mouseInterferon Regulatory Factor-7Interferon-Stimulated Gene Factor 3, gamma SubunitInterferon Type IIrf7 protein, mouseIsgf3g protein, mouseReceptor, Interferon alpha-betaCD8+ T cell exhaustioninterferon regulatory factor 9lymphocytic choriomeningitis virustype I interferon
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.